We’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
Functional and Long-Term Survival Benefit of AMX0035 in ALS
Lead Author: Sabrina Paganoni, MD, PhD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: September 30, 2020
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Lead Author: Sabrina Paganoni, MD, PhD
Published: New England Journal of Medicine
Date: September 3, 2020
Safety, Efficacy and Pharmacokinetics of Repeat Subcutaneous Dosing of Avexitide (Exendin 9-39) for Treatment of Post-Bariatric Hypoglycaemia
Lead Author: Marilyn Tan, MD, FACE
Published: Diabetes, Obesity and Metabolism
Date: August 1, 2020
Clinical Trial Design for a Phase II, Randomized Placebo-Controlled Trial of AMX0035 in Alzheimer’s Disease
Lead Author: Kent L. Leslie
Published: Alzheimer’s Association International Conference (AAIC)
Date: July 24, 2018
Efficacy and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycaemia
Lead Author: Colleen M. Craig, MD
Published: Diabetes, Obesity and Metabolism
Date: February 1, 2018
Clinical Trial Design for a Phase II, Randomized, Placebo-Controlled Trial of AMX0035 in Amyotrophic Lateral Sclerosis (CENTAUR)
Lead Author: Joshua Cohen, Co-CEO and Co-Founder, Amylyx Pharmaceuticals
Published: International Symposium on ALS-MND (MNDA)
Date: December 9, 2017
Evaluation of AMX0035, a Novel Combination Therapy for the Treatment of Neurodegenerative Diseases, in Cellular Models of Friedreich’s Ataxia
Lead Author: Kent L. Leslie
Published: International Ataxia Research Conference
Date: September 29, 2017
AMX0035, a Novel Combination Therapeutic Candidate for Treatment of Primary Mitochondrial Diseases
Lead Author: Kent L. Leslie
Published: United Mitochondrial Disease Foundation Mitochondrial Medicine
Date: June 29, 2017
Critical Role for GLP-1 in Symptomatic Post-Bariatric Hypoglycaemia
Lead Author: Colleen M. Craig, MD
Published: Diabetologia
Date: March 1, 2017
Exendin-(9–39) Corrects Fasting Hypoglycemia in SUR-1–/– Mice by Lowering cAMP in Pancreatic β-Cells and Inhibiting Insulin Secretion
Lead Author: Diva D. De León, MD
Published: Metabolism and Bioenergetics
Date: September 1, 2008